The Experts below are selected from a list of 20043 Experts worldwide ranked by ideXlab platform
Marc W Münter - One of the best experts on this subject based on the ideXlab platform.
-
CASE REPORT Open Access Carbon Ion Therapy for ameloblastic carcinoma
2013Co-Authors: Ra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Ameloblastic carcinomas are rare odontogenic tumors. Treatment usually consists of surgical resectIon and sometimes adjuvant radiatIon. We report the case of a 71 year-old male patient undergoing carbon Ion Therapy for extensive local relapse of ameloblastic carcinoma. Treatment outcome was favourable with a complete remissIon at 6 weeks post completIon of radioTherapy while RT-treatment itself was tolerated well with only mild side effects. High dose radiatIon hence is a potential alternative for patients unfit or unwilling to undergo extensive surgery or in cases when only a subtotal resectIon is planned or the resectIon is mutilating
-
Robotic-based carbon Ion Therapy and patient positIoning in 6 degrees of freedom: setup accuracy of two standard immobilizatIon devices used in carbon Ion Therapy and IMRT.
Radiation oncology (London England), 2012Co-Authors: Alexandra D Jensen, Jürgen Debus, Marcus Winter, Sabine Kuhn, Olaf Nairz, Marc W MünterAbstract:To investigate repositIoning accuracy in particle radioTherapy in 6 degrees of freedom (DOF) and intensity-modulated radioTherapy (IMRT, 3 DOF) for two immobilizatIon devices (Scotchcast masks vs thermoplastic head masks) currently in use at our institutIon for fractIonated radiatIon Therapy in head and neck cancer patients. PositIon verificatIons in patients treated with carbon Ion Therapy and IMRT for head and neck malignancies were evaluated. Most patients received combined treatment regimen (IMRT plus carbon Ion boost), immobilizatIon was achieved with either Scotchcast or thermoplastic head masks. PositIon correctIons in robotic-based carbon Ion Therapy allowing 6 DOF were compared to IMRT allowing correctIons in 3 DOF for two standard immobilizatIon devices. In total, 838 set-up controls of 38 patients were analyzed. Robotic-based positIon correctIon including correctIon of rotatIons was well tolerated and without discomfort. Standard deviatIons of translatIonal components were between 0.5 and 0.8 mm for Scotchcast and 0.7 and 1.3 mm for thermoplastic masks in 6 DOF and 1.2 - 1.4 mm and 1.0 - 1.1 mm in 3 DOF respectively. Mean overall displacement vectors were between 2.1 mm (Scotchcast) and 2.9 mm (thermoplastic masks) in 6 DOF and 3.9 - 3.0 mm in 3 DOF respectively. Displacement vectors were lower when correctIon in 6 DOF was allowed as opposed to 3 DOF only, which was maintained at the traditIonal actIon level of > 3 mm for positIon correctIon in the pre-on-board imaging era. Setup accuracy for both systems was within the expected range. Smaller shifts were required when 6 DOF were available for correctIon as opposed to 3 DOF. Where highest possible positIoning accuracy is required, frequent image guidance is mandatory to achieve best possible plan delivery and maintenance of sharp gradients and optimal normal tissue sparing inherent in carbon Ion Therapy.
-
Carbon Ion Therapy for advanced sinonasal malignancies: feasibility and acute toxicity
Radiation oncology (London England), 2011Co-Authors: Alexandra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Purpose To evaluate feasibility and toxicity of carbon Ion Therapy for treatment of sinonasal malignancies. First site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-field, local control hence calls for dose escalatIon which has so far been hampered by accompanying acute and late toxicity. Raster-scanned carbon Ion Therapy offers the advantage of sharp dose gradients promising increased dose applicatIon without increase of side-effects.
-
Carbon Ion Therapy for advanced sinonasal malignancies: feasibility and acute toxicity
Radiation Oncology, 2011Co-Authors: Alexandra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Purpose To evaluate feasibility and toxicity of carbon Ion Therapy for treatment of sinonasal malignancies. First site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-field, local control hence calls for dose escalatIon which has so far been hampered by accompanying acute and late toxicity. Raster-scanned carbon Ion Therapy offers the advantage of sharp dose gradients promising increased dose applicatIon without increase of side-effects. Methods Twenty-nine patients with various sinonasal malignancies were treated from 11/2009 to 08/2010. Accompanying toxicity was evaluated according to CTCAE v.4.0. Tumor response was assessed according to RECIST. Results Seventeen patients received treatment as definitive RT, 9 for local relapse, 2 for re-irradiatIon. All patients had T4 tumours (median CTV1 129.5 cc, CTV2 395.8 cc), mostly originating from the maxillary sinus. Median dose was 73 GyE mostly in mixed beam technique as IMRT plus carbon Ion boost. Median follow- up was 5.1 months [range: 2.4 - 10.1 months]. There were 7 cases with grade 3 toxicity (mucositis, dysphagia) but no other higher grade acute reactIons; 6 patients developed grade 2 conjunctivits, no case of early visual impairment. Apart from alteratIons of taste, all symptoms had resolved at 8 weeks post RT. Overall radiological response rate was 50% (CR and PR). ConclusIon Carbon Ion Therapy is feasible; despite high doses, acute reactIons were not increased and generally resolved within 8 weeks post radioTherapy. Treatment response is encouraging though follow-up is too short to estimate control rates or evaluate potential late effects. Controlled trials are warranted.
-
Carbon Ion Therapy for ameloblastic carcinoma
Radiation Oncology, 2011Co-Authors: Alexandra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Ameloblastic carcinomas are rare odontogenic tumors. Treatment usually consists of surgical resectIon and sometimes adjuvant radiatIon. We report the case of a 71 year-old male patient undergoing carbon Ion Therapy for extensive local relapse of ameloblastic carcinoma. Treatment outcome was favourable with a complete remissIon at 6 weeks post completIon of radioTherapy while RT-treatment itself was tolerated well with only mild side effects. High dose radiatIon hence is a potential alternative for patients unfit or unwilling to undergo extensive surgery or in cases when only a subtotal resectIon is planned or the resectIon is mutilating.
Jürgen Debus - One of the best experts on this subject based on the ideXlab platform.
-
Ion Therapy of prostate cancer: daily rectal dose reductIon by applicatIon of spacer gel
Radiation oncology (London England), 2015Co-Authors: Antoni Rucinski, Jürgen Debus, Thomas Haberer, Christoph Bert, Stephan Brons, Daniel Richter, Gregor Habl, Oliver JäkelAbstract:Background Ion beam Therapy represents a promising approach to treat prostate cancer, mainly due to its high conformity and radiobiological effectiveness. However, the presence of prostate motIon, patient positIoning and range uncertainties may deteriorate target dose and increase exposure of organs at risk. Spacer gel injected between prostate and rectum may increase the safety of prostate cancer (PC) radiatIon Therapy by separating the rectum from the target dose field. The dosimetric impact of the applicatIon of spacer gel for scanned carbon Ion Therapy of PC has been analyzed at Heidelberg Ion-Beam Therapy Center (HIT).
-
CASE REPORT Open Access Carbon Ion Therapy for ameloblastic carcinoma
2013Co-Authors: Ra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Ameloblastic carcinomas are rare odontogenic tumors. Treatment usually consists of surgical resectIon and sometimes adjuvant radiatIon. We report the case of a 71 year-old male patient undergoing carbon Ion Therapy for extensive local relapse of ameloblastic carcinoma. Treatment outcome was favourable with a complete remissIon at 6 weeks post completIon of radioTherapy while RT-treatment itself was tolerated well with only mild side effects. High dose radiatIon hence is a potential alternative for patients unfit or unwilling to undergo extensive surgery or in cases when only a subtotal resectIon is planned or the resectIon is mutilating
-
Robotic-based carbon Ion Therapy and patient positIoning in 6 degrees of freedom: setup accuracy of two standard immobilizatIon devices used in carbon Ion Therapy and IMRT.
Radiation oncology (London England), 2012Co-Authors: Alexandra D Jensen, Jürgen Debus, Marcus Winter, Sabine Kuhn, Olaf Nairz, Marc W MünterAbstract:To investigate repositIoning accuracy in particle radioTherapy in 6 degrees of freedom (DOF) and intensity-modulated radioTherapy (IMRT, 3 DOF) for two immobilizatIon devices (Scotchcast masks vs thermoplastic head masks) currently in use at our institutIon for fractIonated radiatIon Therapy in head and neck cancer patients. PositIon verificatIons in patients treated with carbon Ion Therapy and IMRT for head and neck malignancies were evaluated. Most patients received combined treatment regimen (IMRT plus carbon Ion boost), immobilizatIon was achieved with either Scotchcast or thermoplastic head masks. PositIon correctIons in robotic-based carbon Ion Therapy allowing 6 DOF were compared to IMRT allowing correctIons in 3 DOF for two standard immobilizatIon devices. In total, 838 set-up controls of 38 patients were analyzed. Robotic-based positIon correctIon including correctIon of rotatIons was well tolerated and without discomfort. Standard deviatIons of translatIonal components were between 0.5 and 0.8 mm for Scotchcast and 0.7 and 1.3 mm for thermoplastic masks in 6 DOF and 1.2 - 1.4 mm and 1.0 - 1.1 mm in 3 DOF respectively. Mean overall displacement vectors were between 2.1 mm (Scotchcast) and 2.9 mm (thermoplastic masks) in 6 DOF and 3.9 - 3.0 mm in 3 DOF respectively. Displacement vectors were lower when correctIon in 6 DOF was allowed as opposed to 3 DOF only, which was maintained at the traditIonal actIon level of > 3 mm for positIon correctIon in the pre-on-board imaging era. Setup accuracy for both systems was within the expected range. Smaller shifts were required when 6 DOF were available for correctIon as opposed to 3 DOF. Where highest possible positIoning accuracy is required, frequent image guidance is mandatory to achieve best possible plan delivery and maintenance of sharp gradients and optimal normal tissue sparing inherent in carbon Ion Therapy.
-
Carbon Ion Therapy for advanced sinonasal malignancies: feasibility and acute toxicity
Radiation oncology (London England), 2011Co-Authors: Alexandra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Purpose To evaluate feasibility and toxicity of carbon Ion Therapy for treatment of sinonasal malignancies. First site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-field, local control hence calls for dose escalatIon which has so far been hampered by accompanying acute and late toxicity. Raster-scanned carbon Ion Therapy offers the advantage of sharp dose gradients promising increased dose applicatIon without increase of side-effects.
-
Carbon Ion Therapy for advanced sinonasal malignancies: feasibility and acute toxicity
Radiation Oncology, 2011Co-Authors: Alexandra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Purpose To evaluate feasibility and toxicity of carbon Ion Therapy for treatment of sinonasal malignancies. First site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-field, local control hence calls for dose escalatIon which has so far been hampered by accompanying acute and late toxicity. Raster-scanned carbon Ion Therapy offers the advantage of sharp dose gradients promising increased dose applicatIon without increase of side-effects. Methods Twenty-nine patients with various sinonasal malignancies were treated from 11/2009 to 08/2010. Accompanying toxicity was evaluated according to CTCAE v.4.0. Tumor response was assessed according to RECIST. Results Seventeen patients received treatment as definitive RT, 9 for local relapse, 2 for re-irradiatIon. All patients had T4 tumours (median CTV1 129.5 cc, CTV2 395.8 cc), mostly originating from the maxillary sinus. Median dose was 73 GyE mostly in mixed beam technique as IMRT plus carbon Ion boost. Median follow- up was 5.1 months [range: 2.4 - 10.1 months]. There were 7 cases with grade 3 toxicity (mucositis, dysphagia) but no other higher grade acute reactIons; 6 patients developed grade 2 conjunctivits, no case of early visual impairment. Apart from alteratIons of taste, all symptoms had resolved at 8 weeks post RT. Overall radiological response rate was 50% (CR and PR). ConclusIon Carbon Ion Therapy is feasible; despite high doses, acute reactIons were not increased and generally resolved within 8 weeks post radioTherapy. Treatment response is encouraging though follow-up is too short to estimate control rates or evaluate potential late effects. Controlled trials are warranted.
Alexandra D Jensen - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of pediatric patients and young adults with particle Therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data
Radiation oncology (London England), 2012Co-Authors: Stephanie E. Combs, Alexandra D Jensen, Swantje Ecker, Angelika Hoess, Kerstin A. Kessel, Klaus Herfarth, Susanne Oertel, Claudia Blattmann, Eike Martin, Olaf WittAbstract:Background To report on establishment of workflow and clinical results of particle Therapy at the Heidelberg Ion Therapy Center.
-
Robotic-based carbon Ion Therapy and patient positIoning in 6 degrees of freedom: setup accuracy of two standard immobilizatIon devices used in carbon Ion Therapy and IMRT.
Radiation oncology (London England), 2012Co-Authors: Alexandra D Jensen, Jürgen Debus, Marcus Winter, Sabine Kuhn, Olaf Nairz, Marc W MünterAbstract:To investigate repositIoning accuracy in particle radioTherapy in 6 degrees of freedom (DOF) and intensity-modulated radioTherapy (IMRT, 3 DOF) for two immobilizatIon devices (Scotchcast masks vs thermoplastic head masks) currently in use at our institutIon for fractIonated radiatIon Therapy in head and neck cancer patients. PositIon verificatIons in patients treated with carbon Ion Therapy and IMRT for head and neck malignancies were evaluated. Most patients received combined treatment regimen (IMRT plus carbon Ion boost), immobilizatIon was achieved with either Scotchcast or thermoplastic head masks. PositIon correctIons in robotic-based carbon Ion Therapy allowing 6 DOF were compared to IMRT allowing correctIons in 3 DOF for two standard immobilizatIon devices. In total, 838 set-up controls of 38 patients were analyzed. Robotic-based positIon correctIon including correctIon of rotatIons was well tolerated and without discomfort. Standard deviatIons of translatIonal components were between 0.5 and 0.8 mm for Scotchcast and 0.7 and 1.3 mm for thermoplastic masks in 6 DOF and 1.2 - 1.4 mm and 1.0 - 1.1 mm in 3 DOF respectively. Mean overall displacement vectors were between 2.1 mm (Scotchcast) and 2.9 mm (thermoplastic masks) in 6 DOF and 3.9 - 3.0 mm in 3 DOF respectively. Displacement vectors were lower when correctIon in 6 DOF was allowed as opposed to 3 DOF only, which was maintained at the traditIonal actIon level of > 3 mm for positIon correctIon in the pre-on-board imaging era. Setup accuracy for both systems was within the expected range. Smaller shifts were required when 6 DOF were available for correctIon as opposed to 3 DOF. Where highest possible positIoning accuracy is required, frequent image guidance is mandatory to achieve best possible plan delivery and maintenance of sharp gradients and optimal normal tissue sparing inherent in carbon Ion Therapy.
-
Carbon Ion Therapy for advanced sinonasal malignancies: feasibility and acute toxicity
Radiation oncology (London England), 2011Co-Authors: Alexandra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Purpose To evaluate feasibility and toxicity of carbon Ion Therapy for treatment of sinonasal malignancies. First site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-field, local control hence calls for dose escalatIon which has so far been hampered by accompanying acute and late toxicity. Raster-scanned carbon Ion Therapy offers the advantage of sharp dose gradients promising increased dose applicatIon without increase of side-effects.
-
Carbon Ion Therapy for advanced sinonasal malignancies: feasibility and acute toxicity
Radiation Oncology, 2011Co-Authors: Alexandra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Purpose To evaluate feasibility and toxicity of carbon Ion Therapy for treatment of sinonasal malignancies. First site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-field, local control hence calls for dose escalatIon which has so far been hampered by accompanying acute and late toxicity. Raster-scanned carbon Ion Therapy offers the advantage of sharp dose gradients promising increased dose applicatIon without increase of side-effects. Methods Twenty-nine patients with various sinonasal malignancies were treated from 11/2009 to 08/2010. Accompanying toxicity was evaluated according to CTCAE v.4.0. Tumor response was assessed according to RECIST. Results Seventeen patients received treatment as definitive RT, 9 for local relapse, 2 for re-irradiatIon. All patients had T4 tumours (median CTV1 129.5 cc, CTV2 395.8 cc), mostly originating from the maxillary sinus. Median dose was 73 GyE mostly in mixed beam technique as IMRT plus carbon Ion boost. Median follow- up was 5.1 months [range: 2.4 - 10.1 months]. There were 7 cases with grade 3 toxicity (mucositis, dysphagia) but no other higher grade acute reactIons; 6 patients developed grade 2 conjunctivits, no case of early visual impairment. Apart from alteratIons of taste, all symptoms had resolved at 8 weeks post RT. Overall radiological response rate was 50% (CR and PR). ConclusIon Carbon Ion Therapy is feasible; despite high doses, acute reactIons were not increased and generally resolved within 8 weeks post radioTherapy. Treatment response is encouraging though follow-up is too short to estimate control rates or evaluate potential late effects. Controlled trials are warranted.
-
Carbon Ion Therapy for ameloblastic carcinoma
Radiation Oncology, 2011Co-Authors: Alexandra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Ameloblastic carcinomas are rare odontogenic tumors. Treatment usually consists of surgical resectIon and sometimes adjuvant radiatIon. We report the case of a 71 year-old male patient undergoing carbon Ion Therapy for extensive local relapse of ameloblastic carcinoma. Treatment outcome was favourable with a complete remissIon at 6 weeks post completIon of radioTherapy while RT-treatment itself was tolerated well with only mild side effects. High dose radiatIon hence is a potential alternative for patients unfit or unwilling to undergo extensive surgery or in cases when only a subtotal resectIon is planned or the resectIon is mutilating.
Oliver Jäkel - One of the best experts on this subject based on the ideXlab platform.
-
Ion Therapy of prostate cancer: daily rectal dose reductIon by applicatIon of spacer gel
Radiation oncology (London England), 2015Co-Authors: Antoni Rucinski, Jürgen Debus, Thomas Haberer, Christoph Bert, Stephan Brons, Daniel Richter, Gregor Habl, Oliver JäkelAbstract:Background Ion beam Therapy represents a promising approach to treat prostate cancer, mainly due to its high conformity and radiobiological effectiveness. However, the presence of prostate motIon, patient positIoning and range uncertainties may deteriorate target dose and increase exposure of organs at risk. Spacer gel injected between prostate and rectum may increase the safety of prostate cancer (PC) radiatIon Therapy by separating the rectum from the target dose field. The dosimetric impact of the applicatIon of spacer gel for scanned carbon Ion Therapy of PC has been analyzed at Heidelberg Ion-Beam Therapy Center (HIT).
-
The impact of modeling nuclear fragmentatIon on delivered dose and radiobiology in Ion Therapy
Physics in medicine and biology, 2012Co-Authors: Armin Lühr, Oliver Jäkel, David C. Hansen, Ricky Teiwes, Nikolai Sobolevsky, Niels BasslerAbstract:The importance of nuclear interactIons for Ion Therapy arises from the influence of the particle spectrum on, first, radiobiology and therefore also on treatment planning, second, the accuracy of measuring dose and, third, the delivered dose distributIon. This study tries to determine the qualitative as well as the quantitative influence of the modeling of inelastic nuclear interactIons on Ion Therapy. Thereby, three key disciplines are investigated, namely dose delivery, dose assessment and radiobiology. In order to perform a quantitative analysis, a relative comparison between six different descriptIons of nuclear interactIons is carried out for carbon Ions. The particle transport is simulated with the Monte Carlo code SHIELD-HIT10A while dose planning and radiobiology are covered by the analytic treatment planning program for particles TRiP, which determines the relative biological effectiveness (RBE) with the local effect model. The obtained results show that the physical dose distributIon can in principle be significantly influenced by the modeling of fragmentatIon (about 10% for a 20% change in all inelastic nuclear cross sectIons for a target volume ranging from 15 to 25 cm). While the impact of nuclear fragmentatIon on stopping power ratios can be neglected, the fluence correctIon factor may be influenced by the applied nuclear models. In contrast to the results for the physical dose, the variatIon of the RBE is only small (about 1% for a 20% change in all inelastic nuclear cross sectIons) suggesting a relatively weak dependence of radiobiology on the detailed compositIon of the particle energy spectrum of the mixed radiatIon field. Also, no significant change (about 0.2 mm) of the lateral penumbra of the RBE-weighted dose is observed.
-
Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients
Acta oncologica (Stockholm Sweden), 2010Co-Authors: Stephanie E. Combs, Alexandra D Jensen, Malte Ellerbrock, Marc W Münter, Oliver Jäkel, Thomas Haberer, Daniel Habermehl, Angelika Hoess, Swantje Klemm, Jakob NaumannAbstract:AbstractThe Heidelberg Ion Therapy Center (HIT) started clinical operatIon in November 2009. In this report we present the first 80 patients treated with proton and carbon Ion radioTherapy and describe patient selectIon, treatment planning and daily treatment for different indicatIons. Patients and methods. Between November 15, 2009 and April 15, 2010, 80 patients were treated at the Heidelberg Ion Therapy Center (HIT) with carbon Ion and proton radioTherapy. Main treated indicatIons consisted of skull base chordoma (n = 9) and chondrosarcoma (n = 18), malignant salivary gland tumors (n=29), chordomas of the sacrum (n = 5), low grade glioma (n=3), primary and recurrent malignant astrocytoma and glioblastoma (n=7) and well as osteosarcoma (n = 3). Of these patients, four pediatric patients aged under 18 years were treated. Results. All patients were treated using the intensity-modulated rasterscanning technique. Seventy six patients were treated with carbon Ions (95%), and four patients were treated with p...
-
particle Therapy at the heidelberg Ion Therapy center hit integrated research driven university hospital based radiatIon oncology service in heidelberg germany
Radiotherapy and Oncology, 2010Co-Authors: Stephanie E. Combs, Oliver Jäkel, Thomas Haberer, Jürgen DebusAbstract:The Heidelberg Ion Therapy Center (HIT) offers treatment of particle Therapy with variety of Ion species for over 1300 patients yearly. In November 2009, patient treatment has begun. The aim of the center is to provide high-end radioTherapy, and to define the role of particle Therapy through clinical trials.
-
Use of Gafchromic® EBT films in heavy Ion Therapy
Nuclear Instruments and Methods in Physics Research Section A: Accelerators Spectrometers Detectors and Associated Equipment, 2008Co-Authors: M. Martišíková, B. Ackermann, S. Klemm, Oliver JäkelAbstract:Abstract Properties of a new type of radiochromic film—Gafchromic EBT—were investigated with respect to its use in heavy Ion Therapy. For this purpose not only radiatIon imaging, but also quantitative dosimetry is desirable. Improvements with respect to older types of Gafchromic films as well as an excellent spatial resolutIon make it to a promising candidate to be used in scanned medical Ion beams. First, the influence of several effects and parameters on the net optical density measured using a commercial flatbed scanner was analyzed. Here the scanner resolutIon, the light scattering effect, the longtime development of the film and multiple evaluatIons of the film were investigated. Methods to reduce the influence of the largest sources of distortIons were proposed. In carbon Ion beams, the signal was observed to be equal or lower than in photon beams at the same dose, depending on the linear energy transfer. This behavior, known also for other dosimetric media, is caused by a local (microscopic) saturatIon which occurs around highly Ionizing Ion tracks. However, the overall darkening of the film was found not to saturate in the regIon of clinically used doses and beyond.
Malte Ellerbrock - One of the best experts on this subject based on the ideXlab platform.
-
CASE REPORT Open Access Carbon Ion Therapy for ameloblastic carcinoma
2013Co-Authors: Ra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Ameloblastic carcinomas are rare odontogenic tumors. Treatment usually consists of surgical resectIon and sometimes adjuvant radiatIon. We report the case of a 71 year-old male patient undergoing carbon Ion Therapy for extensive local relapse of ameloblastic carcinoma. Treatment outcome was favourable with a complete remissIon at 6 weeks post completIon of radioTherapy while RT-treatment itself was tolerated well with only mild side effects. High dose radiatIon hence is a potential alternative for patients unfit or unwilling to undergo extensive surgery or in cases when only a subtotal resectIon is planned or the resectIon is mutilating
-
Carbon Ion Therapy for advanced sinonasal malignancies: feasibility and acute toxicity
Radiation Oncology, 2011Co-Authors: Alexandra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Purpose To evaluate feasibility and toxicity of carbon Ion Therapy for treatment of sinonasal malignancies. First site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-field, local control hence calls for dose escalatIon which has so far been hampered by accompanying acute and late toxicity. Raster-scanned carbon Ion Therapy offers the advantage of sharp dose gradients promising increased dose applicatIon without increase of side-effects. Methods Twenty-nine patients with various sinonasal malignancies were treated from 11/2009 to 08/2010. Accompanying toxicity was evaluated according to CTCAE v.4.0. Tumor response was assessed according to RECIST. Results Seventeen patients received treatment as definitive RT, 9 for local relapse, 2 for re-irradiatIon. All patients had T4 tumours (median CTV1 129.5 cc, CTV2 395.8 cc), mostly originating from the maxillary sinus. Median dose was 73 GyE mostly in mixed beam technique as IMRT plus carbon Ion boost. Median follow- up was 5.1 months [range: 2.4 - 10.1 months]. There were 7 cases with grade 3 toxicity (mucositis, dysphagia) but no other higher grade acute reactIons; 6 patients developed grade 2 conjunctivits, no case of early visual impairment. Apart from alteratIons of taste, all symptoms had resolved at 8 weeks post RT. Overall radiological response rate was 50% (CR and PR). ConclusIon Carbon Ion Therapy is feasible; despite high doses, acute reactIons were not increased and generally resolved within 8 weeks post radioTherapy. Treatment response is encouraging though follow-up is too short to estimate control rates or evaluate potential late effects. Controlled trials are warranted.
-
Carbon Ion Therapy for advanced sinonasal malignancies: feasibility and acute toxicity
Radiation oncology (London England), 2011Co-Authors: Alexandra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Purpose To evaluate feasibility and toxicity of carbon Ion Therapy for treatment of sinonasal malignancies. First site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-field, local control hence calls for dose escalatIon which has so far been hampered by accompanying acute and late toxicity. Raster-scanned carbon Ion Therapy offers the advantage of sharp dose gradients promising increased dose applicatIon without increase of side-effects.
-
Carbon Ion Therapy for ameloblastic carcinoma
Radiation Oncology, 2011Co-Authors: Alexandra D Jensen, Swantje Ecker, Malte Ellerbrock, Anna Nikoghosyan, Jürgen Debus, Marc W MünterAbstract:Ameloblastic carcinomas are rare odontogenic tumors. Treatment usually consists of surgical resectIon and sometimes adjuvant radiatIon. We report the case of a 71 year-old male patient undergoing carbon Ion Therapy for extensive local relapse of ameloblastic carcinoma. Treatment outcome was favourable with a complete remissIon at 6 weeks post completIon of radioTherapy while RT-treatment itself was tolerated well with only mild side effects. High dose radiatIon hence is a potential alternative for patients unfit or unwilling to undergo extensive surgery or in cases when only a subtotal resectIon is planned or the resectIon is mutilating.
-
Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients
Acta oncologica (Stockholm Sweden), 2010Co-Authors: Stephanie E. Combs, Alexandra D Jensen, Malte Ellerbrock, Marc W Münter, Oliver Jäkel, Thomas Haberer, Daniel Habermehl, Angelika Hoess, Swantje Klemm, Jakob NaumannAbstract:AbstractThe Heidelberg Ion Therapy Center (HIT) started clinical operatIon in November 2009. In this report we present the first 80 patients treated with proton and carbon Ion radioTherapy and describe patient selectIon, treatment planning and daily treatment for different indicatIons. Patients and methods. Between November 15, 2009 and April 15, 2010, 80 patients were treated at the Heidelberg Ion Therapy Center (HIT) with carbon Ion and proton radioTherapy. Main treated indicatIons consisted of skull base chordoma (n = 9) and chondrosarcoma (n = 18), malignant salivary gland tumors (n=29), chordomas of the sacrum (n = 5), low grade glioma (n=3), primary and recurrent malignant astrocytoma and glioblastoma (n=7) and well as osteosarcoma (n = 3). Of these patients, four pediatric patients aged under 18 years were treated. Results. All patients were treated using the intensity-modulated rasterscanning technique. Seventy six patients were treated with carbon Ions (95%), and four patients were treated with p...
